|
|
News Breaks
|
November 30, 2009
|
| 12:44 EDT |  | IMGN |
| theflyonthewall.com: | ImmunoGen option prices elevated into data | | ImmunoGen is recently down 58c to $7.57. ImmunoGen most advanced compound, trastuzumab-DM1 (breast cancer treatment) is in Phase three testing, and data is expected before year end. ImmunGen December 7.5 straddle is priced at $2.05, January 7.5 straddle is priced at $3.00. IMGN December and January option implied volatility of 146 is above its 26-week average of 83 according to Track Data, suggesting large price movement. :theflyonthewall.com |
|
|
News For IMGN From The Last 14 Days Check below for free stories on IMGN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
